Cibc World Markets Corp increased its position in Eli Lilly and Company (NYSE:LLY) by 360.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 467,359 shares of the company’s stock after acquiring an additional 365,967 shares during the quarter. Cibc World Markets Corp’s holdings in Eli Lilly and were worth $38,464,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after purchasing an additional 59,978,664 shares during the period. Dodge & Cox boosted its stake in Eli Lilly and by 22,094.9% in the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after purchasing an additional 5,964,955 shares during the period. Vanguard Group Inc. boosted its stake in Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after purchasing an additional 2,181,701 shares during the period. Winslow Capital Management LLC boosted its stake in Eli Lilly and by 79.7% in the 1st quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock worth $326,008,000 after purchasing an additional 1,719,538 shares during the period. Finally, Harbour Capital Advisors LLC boosted its stake in Eli Lilly and by 7,919.1% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,705,338 shares of the company’s stock worth $20,721,000 after purchasing an additional 1,684,072 shares during the period. 75.48% of the stock is owned by institutional investors.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total value of $14,590,800.00. Following the transaction, the insider now directly owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The disclosure for this sale can be found here. Insiders sold a total of 772,003 shares of company stock worth $64,837,441 over the last ninety days. Insiders own 0.20% of the company’s stock.
Several research analysts have commented on LLY shares. Credit Suisse Group downgraded Eli Lilly and from an “outperform” rating to a “neutral” rating and raised their target price for the stock from $84.23 to $88.00 in a research note on Tuesday, October 10th. Piper Jaffray Companies reiterated a “buy” rating and set a $103.00 price target on shares of Eli Lilly and in a research report on Thursday, August 31st. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price target for the company in a research report on Thursday, October 26th. Jefferies Group LLC reiterated a “buy” rating and set a $89.00 price target (down previously from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the company a “sell” rating in a research report on Wednesday, November 1st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. Eli Lilly and currently has a consensus rating of “Hold” and a consensus price target of $89.76.
COPYRIGHT VIOLATION NOTICE: “Cibc World Markets Corp Purchases 365,967 Shares of Eli Lilly and Company (LLY)” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://transcriptdaily.com/2017/11/15/cibc-world-markets-corp-purchases-365967-shares-of-eli-lilly-and-company-lly.html.
Eli Lilly and Company (LLY) opened at $82.49 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The company has a market capitalization of $91,236.74, a P/E ratio of 20.26, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.88 EPS. equities analysts predict that Eli Lilly and Company will post 4.22 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a $0.52 dividend. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.52%. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.